Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T-cell receptor diversity

Immunology

Volumn 129, Issue 1, 2010, Pages 41-54

  Shanker, Anil ^a,b,c   Buferne, Michel ^a,b,c   Schmitt Verhulst, Anne Marie ^a,b,c  

^a CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^b INSER   (France)

^c CNRS   (France)

Author keywords

Anti tumour cytotoxicity; LdP1A specific T cell receptor transgenic mice; Natural killer cells; Proliferation; T cell activation; Tolerance

Indexed keywords

NATURAL KILLER CELL RECEPTOR NKG2D; NUCLEIC ACID BINDING PROTEIN; RAG PROTEIN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL HETEROGENEITY; CELL INTERACTION; CELL SPECIFICITY; CELL STRAIN; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXIC T LYMPHOCYTE; IMMUNOREACTIVITY; LYMPHOCYTE COUNT; MASTOCYTOMA; MOLECULAR MECHANICS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR RESISTANCE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; CELL GROWTH PROCESSES; CLONAL DELETION; IMMUNITY, CELLULAR; KILLER CELLS, NATURAL; LYMPHOCYTE COOPERATION; MASTOCYTOMA; MICE; MICE, INBRED DBA; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, ANTIGEN, T-CELL; T-CELL ANTIGEN RECEPTOR SPECIFICITY;

EID: 71649115681     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2009.03150.x     Document Type: Article

References (36)

1. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002 2: 251 262.
2. Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science 1996 272: 54 60.
3. Sprent J, Surh CD. T cell memory. Annu Rev Immunol 2002 20: 551 579.
4. Wong P, Pamer EG. CD8 T cell responses to infectious pathogens. Annu Rev Immunol 2003 21: 29 70.
5. Mercado R, Vijh S, Allen SE, Kerksiek K, Pilip IM, Pamer EG. Early programming of T cell populations responding to bacterial infection. J Immunol 2000 165: 6833 6839.
6. Kaech SM, Ahmed R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol 2001 2: 415 422.
7. van Stipdonk MJ, Lemmens EE, Schoenberger SP. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol 2001 2: 423 429.
8. Badovinac VP, Porter BB, Harty JT. Programmed contraction of CD8(+) T cells after infection. Nat Immunol 2002 3: 619 626.
9. Verdeil G, Puthier D, Nguyen C, Schmitt-Verhulst AM, Auphan-Anezin N. Gene profiling approach to establish the molecular bases for partial versus full activation of naive CD8 T lymphocytes. Ann N Y Acad Sci 2002 975: 68 76.
10. van Stipdonk MJ, Hardenberg G, Bijker MS, Lemmens EE, Droin NM, Green DR, Schoenberger SP. Dynamic programming of CD8+ T lymphocyte responses. Nat Immunol 2003 4: 361 365.
11. Verdeil G, Puthier D, Nguyen C, Schmitt-Verhulst AM, Auphan-Anezin N. STAT5-mediated signals sustain a TCR-initiated gene expression program toward differentiation of CD8 T cell effectors. J Immunol 2006 176: 4834 4842.
12. Redmond WL, Hernandez J, Sherman LA. Deletion of naive CD8 T cells requires persistent antigen and is not programmed by an initial signal from the tolerogenic APC. J Immunol 2003 171: 6349 6354.
13. Van Der Bruggen P, Zhang Y, Chaux P et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002 188: 51 64.
14. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancertestis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002 188: 22 32.
15. Van den Eynde B, Lethe B, Van Pel A, De Plaen E, Boon T. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA2 mice. J Exp Med 1991 173: 1373 1384.
16. Brandle D, Bilsborough J, Rulicke T, Uyttenhove C, Boon T, Van den Eynde BJ. The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. Eur J Immunol 1998 28: 4010 4019.
17. Van den Eynde B, Mazarguil H, Lethe B, Laval F, Gairin JE. Localization of two cytotoxic T lymphocyte epitopes and three anchoring residues on a single nonameric peptide that binds to H-2Ld and is recognized by cytotoxic T lymphocytes against mouse tumor P815. Eur J Immunol 1994 24: 2740 2745.
18. Shanker A, Auphan-Anezin N, Chomez P, Giraudo L, Eynde BVd, Schmitt-Verhulst A-M. Thymocyte-intrinsic genetic factors influence CD8 T cell lineage commitment and affect selection of a tumor-reactive TCR. J Immunol 2004 172: 5069 5077.
19. Brichard VG, Warnier G, Van Pel A, Morlighem G, Lucas S, Boon T. Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815. Eur J Immunol 1995 25: 664 671.
20. Machy P, Serre K, Baillet M, Leserman L. Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains. J Immunol 2002 168: 1172 1180.
21. Lyons AB, Parish CR. Determination of lymphocyte division by flow cytometry. J Immunol Methods 1994 171: 131 137.
22. Koo GC, Peppard JR. Establishment of monoclonal anti-Nk-1.1 antibody. Hybridoma 1984 3: 301 303.
23. Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002 17: 19 29.
24. Diefenbach A, Hsia JK, Hsiung MY, Raulet DH. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity. Eur J Immunol 2003 33: 381 391.
25. Ma X, Trinchieri G. Regulation of interleukin-12 production in antigen-presenting cells. Adv Immunol 2001 79: 55 92.
26. Galandrini R, Tassi I, Mattia G, Lenti L, Piccoli M, Frati L, Santoni A. SH2-containing inositol phosphatase (SHIP-1) transiently translocates to raft domains and modulates CD16-mediated cytotoxicity in human NK cells. Blood 2002 100: 4581 4589.
27. Sarma S, Guo Y, Guilloux Y, Lee C, Bai XF, Liu Y. Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo. J Exp Med 1999 189: 811 820.
28. Bilsborough J, Van Pel A, Uyttenhove C, Boon T, Van den Eynde BJ. Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815. J Immunol 1999 162: 3534 3540.
29. La Gruta NL, Kedzierska K, Pang K, Webby R, Davenport M, Chen W, Turner SJ, Doherty PC. A virus-specific CD8+ T cell immunodominance hierarchy determined by antigen dose and precursor frequencies. Proc Natl Acad Sci USA 2006 103: 994 999.
30. Markiewicz MA, Fallarino F, Ashikari A, Gajewski TF. Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. Int Immunol 2001 13: 625 632.
31. Marzo AL, Klonowski KD, Le Bon A, Borrow P, Tough DF, Lefrancois L. Initial T cell frequency dictates memory CD8+ T cell lineage commitment. Nat Immunol 2005 6: 793 799.
32. Hataye J, Moon JJ, Khoruts A, Reilly C, Jenkins MK. Naive and memory CD4+ T cell survival controlled by clonal abundance. Science 2006 312: 114 116.
33. Hanson HL, Kang SS, Norian LA, Matsui K, O'Mara LA, Allen PM. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors. J Immunol 2004 172: 4215 4224.
34. Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D et al. Self-antigen- specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med 2009 206: 849 866.
35. Hanson HL, Donermeyer DL, Ikeda H et al. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 2000 13: 265 276.
36. Shanker A, Verdeil G, Buferne M et al. CD8 T cell help for innate antitumor immunity. J Immunol 2007 179: 6651 6662.